ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK

MT Newswires Live

01-07

ARS Pharmaceuticals (SPRY) said Monday it has filed for approval of the neffy epinephrine nasal spray for the treatment of type I allergic reactions in Canada and the UK on behalf of its licensing partner, ALK-Abello.

The company said it is assessing its intranasal epinephrine technology to treat acute flares in patients with chronic urticaria. It intends to initiate a phase 2b clinical trial early this year.

ARS Pharmaceuticals also said its license deal with ALK will provide them exclusive rights for any new indication in the licensed territories under the agreement.

Shares of the company declined more than 1% in recent trading activity.

Price: 10.99, Change: -0.21, Percent Change: -1.83

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2501519672"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501519672\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2501519672?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 00:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501519672","market":"fut","top_or_hot":-1,"title":"ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK","media":"MT Newswires Live","content":"<html><body><p> ARS Pharmaceuticals (SPRY) said Monday it has filed for approval of the neffy epinephrine nasal spray for the treatment of type I allergic reactions in Canada and the UK on behalf of its licensing partner, ALK-Abello.</p><p>The company said it is assessing its intranasal epinephrine technology to treat acute flares in patients with chronic urticaria. It intends to initiate a phase 2b clinical trial early this year.</p><p>ARS Pharmaceuticals also said its license deal with ALK will provide them exclusive rights for any new indication in the licensed territories under the agreement.</p><p>Shares of the company declined more than 1% in recent trading activity.</p><p>Price: 10.99, Change: -0.21, Percent Change: -1.83</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-07 00:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> ARS Pharmaceuticals (SPRY) said Monday it has filed for approval of the neffy epinephrine nasal spray for the treatment of type I allergic reactions in Canada and the UK on behalf of its licensing partner, ALK-Abello.</p><p>The company said it is assessing its intranasal epinephrine technology to treat acute flares in patients with chronic urticaria. It intends to initiate a phase 2b clinical trial early this year.</p><p>ARS Pharmaceuticals also said its license deal with ALK will provide them exclusive rights for any new indication in the licensed territories under the agreement.</p><p>Shares of the company declined more than 1% in recent trading activity.</p><p>Price: 10.99, Change: -0.21, Percent Change: -1.83</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2501519672","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501519672","pubTimestamp":1736179562,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ARS Pharmaceuticals  said Monday it has filed for approval of the neffy epinephrine nasal spray for the treatment of type I allergic reactions in Canada and the UK on behalf of its licensing partner, ALK-Abello.The company said it is assessing its intranasal epinephrine technology to treat acute flares in patients with chronic urticaria. It intends to initiate a phase 2b clinical trial early this year.ARS Pharmaceuticals also said its license deal with ALK will provide them exclusive rights for any new indication in the licensed territories under the agreement.Shares of the company declined more than 1% in recent trading activity.Price: 10.99, Change: -0.21, Percent Change: -1.83","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SPRY":"ARS PHARMACEUTICALS INC"},"translate_title":"ARS Pharmaceuticals在加拿大和英国申请批准实验性过敏反应治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":0.9},"content_text":"ARS Pharmaceuticals (SPRY) said Monday it has filed for approval of the neffy epinephrine nasal spray for the treatment of type I allergic reactions in Canada and the UK on behalf of its licensing partner, ALK-Abello.The company said it is assessing its intranasal epinephrine technology to treat acute flares in patients with chronic urticaria. It intends to initiate a phase 2b clinical trial early this year.ARS Pharmaceuticals also said its license deal with ALK will provide them exclusive rights for any new indication in the licensed territories under the agreement.Shares of the company declined more than 1% in recent trading activity.Price: 10.99, Change: -0.21, Percent Change: -1.83","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1}}}